MSDS Ref. No:
1. PRODUCT AND COMPANY IDENTIFICATION
Lithium Carbonate CHEMICAL FAMILY:
Alkali Carbonates MOLECULAR FORMULA:
Dilithium Carbonate, Carbonic Acid, Dilithium Salt ALTERNATE TRADE NAME(S):
Lithchips® GENERAL USE:
Chemical Manufacturing MANUFACTURER
(Plant) Call Collect 24 Hr/Day Emergency Phone
(Medical) Call Collect
2. COMPOSITION / INFORMATION ON
3. HAZARDS IDENTIFICATION
IMMEDIATE CONCERNS: White granular solid or powder, odorless.
POTENTIAL HEALTH EFFECTS:
Eye irritant; no significant hazard in
industrial/commercial applications. COMMENTS:
(See Section 11, Toxicological Information)
4. FIRST AID MEASURES
Flush with water for at least 15 minutes. If irritation occurs and
persists, contact a medical doctor. SKIN:
Wash with plenty of soap and water. Get medical attention if
irritation occurs and persists. INGESTION:
Drink 1 or 2 glasses of water. Never give anything by
mouth to an unconscious person. If any discomfort persists, obtain medical
Remove to fresh air. If breathing difficulty or
discomfort occurs and persists, obtain medical attention. NOTES TO MEDICAL DOCTOR:
Lithium carbonate has low
toxicity and may produce moderate irritation. Treatment is symptomatic
5. FIRE FIGHTING MEASURES
Not applicable GENERAL HAZARD:
No known physical hazard, non-combustible. EXTINGUISHING MEDIA:
Dry chemical, CO2, water spray or
regular foam. HAZARDOUS COMBUSTION PRODUCTS:
None FIRE FIGHTING PROCEDURES:
Wear full protective clothing
and self-contained breathing apparatus (SCBA) approved for fire fighting.
This is necessary to protect against the hazards of heat, products of
combustion and oxygen deficiency. Do not breathe smoke, gases or vapors
generated. AUTOIGNITION TEMPERATURE:
Not applicable PROPERTIES CONTRIBUTING TO FLAMMABILITY:
None FLASH POINT:
Not applicable SENSITIVITY TO STATIC DISCHARGE:
Not applicable SENSITIVITY TO IMPACT:
(See Section 10, Stability and Reactivity)
6. ACCIDENTAL RELEASE MEASURES
Sweep up and place in suitable container.
Dispose of waste according to local and Federal laws and regulations.
Before cleanup measures begin, review the entire MSDS with particular attention to Section 3, Emergency Overview and Potential Health Effects; and Section 8, Recommended Personal Protective Equipment.
7. HANDLING AND STORAGE
Avoid contact with eyes, skin or clothing. Use with
adequate ventilation. Wear safety glasses or goggles and rubber gloves.
Wash thoroughly after handling. STORAGE:
Keep away from strong acids. Keep container closed.
8. EXPOSURE CONTROLS / PERSONAL
Use local exhaust ventilation to keep
airborne concentrations below exposure limits.
PERSONAL PROTECTIVE EQUIPMENT
EYES AND FACE:
Safety glasses or goggles RESPIRATORY:
When engineering controls are not adequate, wear a
NIOSH/MSHA respirator approved for protection against inorganic dusts. PROTECTIVE CLOTHING:
Rubber gloves WORK HYGIENIC PRACTICES:
Quick-drench eyewash and
9. PHYSICAL AND CHEMICAL PROPERTIES
Solid, white granular or powder pH:
(1% Slurry) @ 25ºC: 11.2 PERCENT VOLATILE:
Not applicable VAPOR PRESSURE:
Not applicable VAPOR DENSITY:
Not applicable BOILING POINT:
Decomposes at 1310°C (2390°F) MELTING POINT:
720ºC (1330ºF) SOLUBILITY IN WATER:
1.3 g/100 cc @ 20ºC EVAPORATION RATE:
Not applicable SPECIFIC GRAVITY:
2.1 g/cc MOLECULAR WEIGHT:
73.89 COEFF. OIL/WATER:
Not applicable ODOR THRESHOLD:
10. STABILITY AND REACTIVITY
CONDITIONS TO AVOID:
Contact with acids STABILITY:
Will not occur HAZARDOUS DECOMPOSITION PRODUCTS:
None INCOMPATIBLE MATERIALS:
11. TOXICOLOGICAL INFORMATION
Moderately irritating (rabbit) [FMC I87-0998] SKIN EFFECTS:
Minimally irritating; PII = 0.3/8.0 (rabbit) [FMC
I87-0999] DERMAL LD :
>2000 mg/kg (rat), [FMC I93-1799]
= 525 mg/kg (rat), [RTECS 1983]
INHALATION LC :
>0.80 mg/L (4 hr. rat); No mortality at
maximum attainable concentration, [FMC I93-1800] SENSITIZATION:
Non-sensitizer (guinea pig) [FMC I93-1801] ACUTE EFFECTS FROM OVEREXPOSURE:
carbonate has low oral and dermal toxicity and is moderately irritating to
the eyes. It is not sensitizing and is essentially non-irritating to the skin. CHRONIC EFFECTS FROM OVEREXPOSURE:
The use of
this product in industrial and commercial applications presents no
significant toxicity hazard. The symptoms described below are based on
therapeutic applications where relatively large doses are taken orally by medically supervised patients.
Lithium carbonate is used therapeutically at 500-2000 mg/day oral doses for specific mental disorders. Therapeutic effects occur at blood levels of 2.8 - 8.3 mg of lithium per liter. Minimal signs of toxicity may also occur at these therapeutic levels and involve primarily gastrointestinal upset. Increased dosage can produce tremors, drowsiness and unsteady gait. Signs of toxicity resolve rapidly on cessation of treatment. Prolonged treatment at toxic levels result in dehydration, kidney damage, weight loss and thyroid disturbances.
Some studies of pregnant mice and rats were associated with birth defects but only at dose levels large enough to produce signs of severe maternal toxicity. Although data from the 1970's and 1980's suggested an increase in cardiovascular defects in babies born in women on lithium carbonate therapy, more recent studies have not found any association between lithium exposure and birth defects. Women receiving therapeutic lithium carbonate treatment at the time of confinement have the potential for delivery of a fetus with poor muscle tone, slowed heart rate and cyanosis. Full recovery usually occurs within 2-10 days postpartum. Therapeutic and greater levels of lithium may pose a risk to the conceptus and potential benefits to the mother are weighed carefully in clinical situations.
Exposure to lithium in industrial settings is not considered to pose a risk to human health. NIOSH studied 25 workers exposed to lithium-containing dust at air concentrations exceeding 10 mg/m³ (nuisance dust limit) and found that typical industrial exposure to lithium will not result in blood levels sufficiently high to produce toxicity in either adults or their offspring. [Health Hazard Evaluation report HHE80-036-922]
IARC: Not listed NTP: Not listed OSHA: Not listed OTHER: ACGIH: Not listed
12. ECOLOGICAL INFORMATION
Lithium carbonate is expected to be moderately toxic to aquatic
invertebrates and freshwater fish.
Daphnia magna: 48 hr. EC50 = 33.2 mg/L [FMC Study I96-2085]
Rainbow trout: 96 hr. LC50 = 30.3 mg/L [FMC Study I96-2086] CHEMICAL FATE INFORMATION:
No data available for the
13. DISPOSAL CONSIDERATIONS
Dispose of waste according to local and
Federal laws and regulations.
14. TRANSPORT INFORMATION
U. S. DOT, INTERNATIONAL MARITIME, AND
Proper Shipping Name: None
UN Number: None
15. REGULATORY INFORMATION
SARA TITLE III (SUPERFUND AMENDMENTS AND
SARA TITLE III SECTION 302 EXTREMELY
HAZARDOUS SUBSTANCES (40 CFR 355):
Not listed SECTION 311 HAZARD CATEGORY (40 CFR 370):
Immediate (Acute) Health Hazard SECTION 313 REPORTABLE INGREDIENTS (40 CFR
This product contains lithium carbonate which is subject to the
reporting requirements of Section 313 of the Emergency Planning and
Right-To-Know Act of 1986.
This information must be included in all MSDS's that are copied and distributed for this material.
CERCLA (COMPREHENSIVE ENVIRONMENTAL RESPONSE
COMPENSATION AND LIABILITY ACT)
CERCLA REGULATORY (40 CFR 302.4):
TSCA (TOXIC SUBSTANCE CONTROL ACT)
TSCA INVENTORY (40 CFR 710, SUBPART B):
is not subject to TSCA 12 (b) Export Notification Requirements. TSCA STATUS (40 CFR 710):
California Proposition 65: WARNING. This product contains a chemical known to the State of California to cause reproductive toxicity.
WHMIS (WORKPLACE HAZARDOUS MATERIALS
Product Identification No.: None
Hazard Classification: Class D, Division 2B (Eye irritant)
Ingredient Disclosure List: Not listed
16. OTHER INFORMATION
Revision #: 3
This MSDS replaces Revision #2, dated June 21, 1999. Any changes in information are as follows: Section(s): 8 & 16
This MSDS has been prepared to meet U. S. OSHA Hazard communication Standard, 29 CFR 1910.1200 and Canada's Workplace Hazardous Materials Information System (WHMIS) requirements. type 1b
2002 FMC Corporation. All Rights Reserved. FMC Lithium, the FMC Lithium logo and Lithchips are trademarks of FMC Corporation.
[email protected] Whose Property Are They? Written and prepared by Dr. Adah Leshem-Ackerman, Department of Zoology & Genetics, Iowa State University. Michelle and Brian Clifford were married for five years before they decided to try to conceive a child. Five years later they were still childless. They contacted Dr. Morgan, a fertility expert, and underwent a series of tests to determi
INTERDISCIPLINARY RESEARCH PROJECT FUNDED BY THE SPECIALISED COMMITTEE INTERDISCIPLINARY RESEARCH OF THE SWISS NATIONAL SCIENCE FOUNDATION (SNSF) Children’s Rights Unit PO Box 4176 • 1950 Sion 4 • Switzerland Tel. +41 27 205 73 00 • Fax +41 27 205 73 01 MAIN FINDINGS • The international priorities of child rights advocacy have significantly evolved over the period under revi